How Nasal Sprays Are Used for Anxiety and Depression
Nasal spray medications deliver drugs directly through the nasal lining into the bloodstream, aiming for faster onset than oral pills. In anxiety and depression treatment, this route is studied for rapid symptom relief, especially in acute or treatment-resistant cases. The U.S. Food and Drug Administration has approved specific nasal spray formulations for psychiatric conditions, and several companies are developing new candidates. Clinical data show measurable changes in depressive and anxiety scores within hours or days in some trials, which is faster than the weeks typical for traditional antidepressants. These products are part of a broader category of rapid-acting psychiatric interventions that also includes intravenous and sublingual options.
Key active ingredients in nasal sprays for these conditions include psychedelics such as psilocybin and non-psychedelic compounds targeting glutamate or opioid pathways. Companies like COMPASS Pathways and MindMed are running late-stage trials, with COMPASS reporting phase 3 data for treatment-resistant depression and MindMed advancing an LSD-based therapy. The FDA has granted breakthrough therapy designations to several of these candidates, which can shorten review timelines. Real-world adoption will depend on safety profiles, pricing, and reimbursement decisions by insurers and government programs. Current market analysis suggests the psychiatric nasal spray segment could grow substantially as new approvals expand the treatment landscape.
Approved and Investigational Nasal Spray Products
Spravato, a nasal spray formulation of esketamine, was approved by the FDA in 2019 for treatment-resistant depression and later for suicidal ideation. It is manufactured by Johnson & Johnson and is typically administered in a certified healthcare setting under a Risk Evaluation and Mitigation Strategy. The drug acts on the NMDA receptor system, offering a different mechanism than selective serotonin reuptake inhibitors. In 2024, real-world data from clinics show that a subset of patients experience rapid mood improvement within 24 hours, though response varies. Spravato is often used alongside oral antidepressants, and its use is covered by many major insurance plans, including Medicare Part D, subject to prior authorization.
Beyond esketamine, investigational nasal sprays include compounds from companies such as Beckley Psytech, which is studying intranasal 5-MeO-DMT for depression and anxiety. The company reported phase 2 data showing significant reductions in depression scores, and the FDA has granted fast track designation for the candidate. Another approach involves neurosteroids and glutamate modulators delivered nasally, aiming to avoid the psychoactive effects associated with classic psychedelics. Regulatory filings and trial registrations on ClinicalTrials.gov list dozens of active studies, with endpoints focused on changes in Hamilton Depression Rating Scale and generalized anxiety disorder scales. Competitive positioning among these products will depend on efficacy durability, side effect profiles, and ease of administration outside clinical settings.
Market, Access, and Practical Considerations
The global market for psychiatric nasal sprays is projected to expand as patent expirations on older antidepressants increase demand for novel delivery systems. Companies are investing in digital health tools to support remote monitoring of patients using these sprays, aiming to improve adherence and safety. Pricing remains a critical factor, with Spravato list prices in the thousands of dollars per treatment course, though manufacturer copay programs and insurance negotiations affect out-of-pocket costs. In the U.S., the SEC filings of publicly traded biotech firms provide detailed financial data on R&D spending and revenue forecasts for these products. Investors and analysts track quarterly earnings calls for updates on regulatory milestones and commercial launch progress.
For patients, practical considerations include the need for in-clinic administration for certain products, potential side effects such as dissociation or elevated blood pressure, and the requirement for a treatment plan that includes psychotherapy. Guidelines from professional societies are evolving to incorporate nasal spray options, especially for individuals who have not responded to multiple oral medications. Real-world evidence from electronic health records and insurance claims databases is beginning to quantify usage patterns and long